Nasal administration of drugs as a new non-invasive strategy for efficient treatment of multiple sclerosis

Journal of Neuroimmunology

Volumn 258, Issue 1-2, 2013, Pages 32-40

  Duchi, Shaher ^a   Ovadia, Haim ^b   Touitou, Elka ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Cannabidiol; Experimental autoimmune encephalomyelitis; Glatiramer acetate; Multiple sclerosis; Nasal drug administration; Neurogenesis

Indexed keywords

CANNABIDIOL; DRUG CARRIER; GLATIRAMER; INTERLEUKIN 6; MESSENGER RNA; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEMALE; HIPPOCAMPUS; HISTOPATHOLOGY; LOW DRUG DOSE; MONOTHERAPY; MOUSE; MULTIPLE SCLEROSIS; NERVE CELL DIFFERENTIATION; NERVE REGENERATION; NEUROPROTECTION; NON INVASIVE PROCEDURE; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; TOXICITY TESTING;

ADMINISTRATION, INTRANASAL; ANIMALS; CANNABIDIOL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED C57BL; MULTIPLE SCLEROSIS; NERVE REGENERATION; PEPTIDES;

EID: 84876732804     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2013.02.013     Document Type: Article

References (27)

1. Aharoni R., Arnon R., Eilam R. Neurogenesis and neuroprotection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis. J. Neurosci. 2005, 25:8217-8228.
2. Arora P., Sharma S., Garg S. Permeability issues in nasal drug delivery. Drug Discov. Today 2002, 7:967-975.
3. Bjartmar C., Trapp B.D. Axonal degeneration and progressive neurologic disability in multiple sclerosis. Neurotox. Res. 2003, 5:157-164.
4. Brod S.A., Lindsey J.W., Wolinsky J.S. Combination therapy with glatiramer acetate (copolymer-1) and a type I interferon (IFN-α) does not improve experimental autoimmune encephalomyelitis. Ann. Neurol. 2000, 47:127-131.
5. Chien Y.W. Nasal drug delivery and delivery systems. Novel Drug Delivery systems 1992, 229-269. Macel Dekker INC., NY. Y.W. Chien (Ed.).
6. Duchi S., Touitou E., Pradella L., Marchini F., Ainbinder D. Nasal tramadol delivery system: a new approach for improved pain therapy. Eur. J. Pain Suppl. 2011, 5:449-452.
7. Giuliani F., Metz L.M., Wilson T., Fan Y., Bar-Or A., Yong V.W. Additive effect of the combination of glatiramer acetate and minocycline in a model of MS. J. Neuroimmunol. 2005, 158:213-221.
8. Giusti A., Giambuzzi M. Management of dysphagia in patients affected by multiple sclerosis: state of the art. Neurol. Sci. 2008, 29:S364-S366.
9. Gross E.A., Swenberg J.A., Fields S., Popp J.A. Comparative morphometry of the nasal cavity in rats and mice. J. Anat. 1982, 135:83-88.
10. Hinchcliffe M., Illum L. Intranasal insulin delivery and therapy. Adv. Drug Deliv. Rev. 1999, 35:199-234.
11. Hjortkjaer R.K., Bechgaard E., Gizurarson S., Suzdak C., McDonald P., Greenough R.J. Single- and repeated-dose local toxicity in the nasal cavity of rabbits after intranasal administration of different glycols for formulations containing benzodiazepines. J. Pharm. Pharmacol. 1999, 51:377-383.
12. Hohfeld R., Barkhof F., Polman C.H. Future clinical challenges in multiple sclerosis: relevance to sphingosine 1-phosphate receptor modulator therapy. Neurology 2011, 76:S28-S37.
13. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur. J. Pharm. Sci. 2000, 11:1-18.
14. Illum L. Nasal drug delivery - possibilities, problems and solutions. J. Control. Release 2003, 87:187-198.
15. Illum L. Is nose-to-brain transport of drugs in man a reality?. J. Pharm. Pharmacol. 2004, 56:3-17.
16. Killestein J., Rudick R.A., Polman C.H. Oral treatment in multiple sclerosis. Lancet Neurol. 2011, 10:1026-1034.
17. Lehmann D., Karussis D.M., Fluresco D., Mizrachi-Koll R., Ovadia H., Shezen E., et al. Immunomodulation of autoimmunity by linomide: inhibition of antigen presentation through down regulation of macrophage activity in the model of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 1997, 74:102-110.
18. Leker R.R., McKay R.D. Using endogenous neural stem cells to enhance recovery from ischemic brain injury. Curr. Neurovasc. Res. 2004, 1:421-427.
19. Licht T., Eavri R., Goshen I., et al. VEGF is required for dendritogenesis of newly born olfactory bulb interneurons. Development 2010, 137:261-271.
20. Malfait A.M., Gallily R., Sumariwalla P.F., Malik A.S., Andreakos E., Mechoulam R., et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:9561-9566.
21. Marttin E., Verhoef J.C., Merkus F.W. Efficacy, safety and mechanism of cyclodextrins as absorption enhancers in nasal delivery of peptide and protein drugs. J. Drug Target. 1998, 6:17-36.
22. Nakai S., Kawakita T., Himeno K., Nomoto K. Combined treatments with Ninjin-youei-to (Ren-shen-yang-rong-tang) plus a suboptimal dose of prednisolone on autoimmune nephritis in MRL/lpr mice. Int. J. Immunopharmacol. 1998, 20:275-284.
23. Ovadia H., Paterson P.Y. Effect of indomethacin treatment upon actively-induced and transferred experimental allergic encephalomyelitis (EAE) in Lewis rats. Clin. Exp. Immunol. 1982, 49:386-392.
24. Simon M., Wittmar M., Kissel T., Linn T. Insulin containing nanocomplexes formed by self-assembly from biodegradable amine-modified poly(vinyl alcohol)-graft-poly(l-lactide): bioavailability and nasal tolerability in rats. Pharm. Res. 2005, 22:1879-1886.
25. Stüve O., Youssef S., Weber M.S., Nessler S., von Büdingen H.C., Hemmer B., et al. Immunomodulatory synergy by combination of glatiramer acetate and atorvastatin in treatment of CNS autoimmunity. J. Clin. Invest. 2006, 116:1037-1044.
26. Stuve O., Bennett J.L., Hemmer B., Wiendl H., Racke M.K., Bar-Or A., et al. Pharmacological treatment of early multiple sclerosis. Drugs 2008, 68:73-83.
27. Uraih L.C., Maronpot R.R. Normal histology of the nasal cavity and application of special techniques. Environ. Health Perspect. 1990, 85:187-208.